ClinicalTrials.gg
RecruitingNCT04518592Updated Apr 24, 2024

Model-based Defining of Subtypes of Depression and Optimal Treatment: an Integrated Techniques Module.

An observational study in Major Depressive Disorder, sponsored by Shanghai Mental Health Center. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-24.

Sponsored by Shanghai Mental Health Center · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Dec 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Depressive Disorder, Major by Shanghai Mental Health Center — 12 open to participants now, 12 under way, none of them phase 3. Depressive Disorder, Major · Shanghai Mental Health Center.

Started
2020
with 6 others
Observational
8 of 40
5 open now
Primary completion
2024-09
later than 1 of 11 live
Registered
17th of 40
by date

Among the 40 studies in Depressive Disorder, Major by Shanghai Mental Health Center, this one is one of 7 that started in 2020, is one of 8 observational ones, reaches primary completion later than 1 of the 11 other live ones, and was the 17th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

12 of the 40 studies in Depressive Disorder, Major by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Depressive Disorder, Major by Shanghai Mental Health Center, or all of them as a file.
02

Study summary

In this proposal, the investigators aim to explore the clinical subtypes and biological markers to personalize the use of antidepressants in MDD. By stratifying the subjects with (versus without) remission and treatment response, the biological markers are expected to have important prediction effects in future clinical practice.

Read the detailed description

In this proposal, through the integration of genome, transcriptome, protein, metabolic group, microbial group and immune cell subtype of multidimensional omics data to construct the curative effect of forecast model.The investigators aim to explore the clinical subtypes and biological markers to personalize the use of antidepressants in MDD. By stratifying the subjects with (versus without) remission and treatment response, the biological markers are expected to have important prediction effects in future clinical practice.Ultimate aim is to solve the depression medication selection dilemma of "trial and error", reduce medical costs, improving depression treatment experience.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Enrollment is constrained to those participants dosed with SSRI/SNRI and healthy controls.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 18-65 years, outpatients or inpatients.
  2. Meets the criteria for Severe Major Depressive Disorder ; a single episode(296.21、296.22、296.23)or recurrent episode (296.31、296.32、296.33);
  3. MADRS score greater than or equal to 24 in baseline;
  4. HAMD-17 score greater than or equal to 20 in baseline.
  5. Patients have learned and voluntarily participated in the study, and have to sign .

Exclusion criteria

Exclusion Criteria:

  1. Meets the criteria for other mental disorder(schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, anxiety disorders, obsessive-compulsive and related disorders, somatic symptom and related disorders, etc ).
  2. Patient has survived suicide attempt , or may have a significant risk for suicidal behavior ,or with a score of >3 on suicidal thoughts item 10 on the MADRS.
  3. Depressive episode of an organic mental disorder secondary to a systemic disease or a central nervous system disease, such as depressive episode secondary to hypothyroidism.
  4. Serious and instable body disease such as cerebrovascular disease, respiratory disease, blood disease, liver and kidney disease, disease of internal secretion, nervous system and other systemic disease.
  5. any history of seizures or other organic brain diseases.
  6. History of alcohol or drug abuse (besides nicotine) over the last 6 months
  7. Serious and instable body disease such as cerebrovascular disease, liver and kidney disease, disease of internal secretion (abnormal thyroid function), blood disease; any history of seizures or other organic brain diseases.
  8. Subjects who can't take drug or have an operation history which affect drug metabolism.
  9. changes in or laboratory tests, including >1.5X liver function、over the limit of normal renal function and blood sugar、abnormal cardiac troponins、obvious abnormity in the thyroid function
  10. Pregnant or lactating women and women of throughout the study period; men who have the desire of fertility within three months;
  11. Participation in other clinical studies in the nearly 1 month before screen.
  12. Other conditions which, in the investigator's judgment, render patients unsuitable for the clinical study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Severe Major Depressive Disorder

    subjects who meet the standards;using conventional antidepressant.

  • control , healthy

    subjects who meet the standards;gender, race, and level of education matched healthy people

06

What researchers measure

Primary outcomes

  1. reductive scores of Montgomery-Asberg Depression Rating Scale(MADRS)

    change in MADRS scores from baseline and week 8

    Time frame: assess the scale at baseline and week 8.

Secondary outcomes

  1. effective rate

    ratio of points of Montgomery-Asberg Depression Rating Scale(MADRS) and/or Hamilton Depression Scale-17(HAMD-17)

    Time frame: assess the scale at baseline and week 8.

  2. Response rate

    Montgomery-Asberg Depression Rating Scale(MADRS) ≤ 10 and/or Hamilton Depression Scale-17(HAMD-17) ≤7

    Time frame: assess the scale at baseline and week 8.

  3. Montgomery-Asberg Depression Rating Scale(MADRS) scores

    Montgomery-Asberg Depression Rating Scale(MADRS) scores at baseline and week 4, 8

    Time frame: assess the scale at baseline and week 4, 8.

  4. Subtraction score

    Hamilton Depression Scale-17(HAMD17) total score after 8 weeks treatment compared with the baseline subtraction score.

    Time frame: assess the scale at baseline and week 4, 8.

  5. The overall evaluation of illness

    the CGI-s (Clinical Global Impression scale - Severity of Illness)rating changes compared to the baseline and CGI - I score.

    Time frame: assess the scale at baseline and week 4, 8.

  6. Hamilton Anxiety Scale

    the scores changes compared to the baseline

    Time frame: assess the scale at baseline and week 4, 8.

  7. The Pittsburgh Sleep Quality Index

    the scores changes compared to the baseline

    Time frame: assess the scale at baseline and week 4, 8.

  8. The Montreal Cognitive Assessment

    the scores changes compared to the baseline

    Time frame: assess the scale at baseline and week 4, 8.

  9. The Quick Inventory of Depressive Symptomatology (16-Item) (Self-Report)

    the scores changes compared to the baseline

    Time frame: assess the scale at baseline and week 4, 8.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Sep 2024, 45 months after the start.

Of 121 non-industry observational studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 73. This study's planned 45 months is close to that.

Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2020
First posted
Aug 19, 2020
StartActual
Dec 22, 2020
Primary completionEst.
Sep 30, 2024
CompletionEst.
Sep 30, 2024
Last update
Apr 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04518592
Responsible party
Sponsor
First posted
Aug 19, 2020
Start date
Dec 22, 2020
Primary completion
Sep 30, 2024 (estimated)
Completion
Sep 30, 2024 (estimated)
Last update
Apr 24, 2024

Study contacts

huafang Li, Phd
Contact
lhlh_5@163.com
86-21-64387250 ext. 3128
huafang Li, Phd
study chair · Study Principal Investigator Drug Clinical Trial Office, Shanghai Mental Health Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion